Menu
Back to Journals » OncoTargets and Therapy » Volume 10
Efficacy of eribulin in breast cancer: a short report on the emerging new data
Authors Eslamian G, Wilson C, Young RJ
Received 29 November 2016
Accepted for publication 14 January 2017
Published 13 February 2017 Volume 2017:10 Pages 773—779
DOI https://doi.org/10.2147/OTT.S102638
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Samir Farghaly
Gelareh Eslamian, Caroline Wilson, Robin J Young
Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK
Abstract: Eribulin is a novel microtubule-targeting agent that is approved for the treatment of patients with locally advanced or metastatic breast cancer who have previously received treatment with an anthracycline and a taxane in either the adjuvant or metastatic setting. Eribulin induces mitotic catastrophe leading to cell death but has other important antitumor effects, including reversal of epithelial–mesenchymal transition and remodeling of the tumor vasculature. Eribulin was licensed for the treatment of advanced breast cancer based on results from two large randomized Phase III clinical trials. Current clinical trials of eribulin for breast cancer are evaluating response to treatment earlier in the patient pathway and in combination with other therapeutic agents. This review provides a short overview of emerging new data on the mode of action of eribulin in breast cancer.
Keywords: eribulin, microtubule-targeting agents, breast cancer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.